Literature DB >> 2348233

Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.

F Buchegger1, A Pèlegrin, B Delaloye, A Bischof-Delaloye, J P Mach.   

Abstract

During one week, beginning 18 days after transplantation, nude mice bearing human colon carcinoma ranging from 115 to 943 mm3 (mean 335 mm3) were treated by repeated intravenous injections of either iodine-131-(131I) labeled intact antibodies or 131I-labeled corresponding F(ab')2 fragments of a pool of four monoclonal antibodies (MAbs) directed against distinct epitopes of carcinoembryonic antigen (CEA). Complete tumor remission was observed in 8 of 10 mice after therapy with F(ab')2 and 6 of the animals survived 10 mo in good health. In contrast, after treatment with intact MAbs, tumors relapsed in 7 of 8 mice after remission periods of 1 to 3.5 mo despite the fact that body weight loss and depression of peripheral white blood cells, symptoms of radiation toxicity, and the calculated radiation doses for liver, spleen, bone, and blood were increased or equal in these animals as compared to mice treated with F(ab')2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2348233

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  24 in total

1.  Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.

Authors:  J M Connett; C J Anderson; L W Guo; S W Schwarz; K R Zinn; B E Rogers; B A Siegel; G W Philpott; M J Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 2.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

3.  The scientific bases of cancer management: at the interface between fundamental research and clinical practice.

Authors:  M Tubiana
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.

Authors:  Robert M Sharkey; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

Review 5.  Radiotheranostic Agents in Hematological Malignancies.

Authors:  Jo Caers; Elodie Duray; Louise Vrancken; Guillaume Marcion; Valentina Bocuzzi; Kim De Veirman; Ahmet Krasniqi; Margaux Lejeune; Nadia Withofs; Nick Devoogdt; Mireille Dumoulin; Amelie Eriksson Karlström; Matthias D'Huyvetter
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

Review 6.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

7.  Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor.

Authors:  O C Boerman; R M Sharkey; G Y Wong; R D Blumenthal; R L Aninipot; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Detection of cervical metastases of thyroid medullary carcinoma by MoAb anti-CEA scintigraphy and immunohistochemistry.

Authors:  S Parkkila; A Ahonen; P Torniainen; J Heikkilä; P Salmela
Journal:  Eur J Nucl Med       Date:  1995-09

9.  Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization.

Authors:  A Ullén; K Riklund Ahlström; R Makiya; T Stigbrand
Journal:  Cell Biophys       Date:  1995-08

10.  Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.

Authors:  G Westera; T Rülicke; A Smith; S Duewell
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.